https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/accelerated-approval-request-new-drug-rare-childhood-muscle-disorder/
Accelerated approval request for a new drug for a rare childhood muscle disorder
9 Sep 2015, 4:41 p.m.
A drug for Duchenne Muscular Dystrophy (DMD), originally developed by BRC Theme Lead Professor Francesco Muntoni’s Consortium in the UK, has been filed by Sarepta Therapeutics for accelerated approval by the United States Food and Drug Adminstration (FDA).The drug Eteplirsen is an antisense oligonucleotide that is designed to enable the production of a functional truncated dystrophin protein to alleviate some of the symptoms of DMD.
DMD is an X-linked rare degenerative neuromuscular disorder that causes severe progressive muscle loss and premature death. It is one of the most common fatal genetic disorders, affecting approximately one in every 3,500 boys born worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fibre function. The condition is universally fatal, and death usually occurs before the age of 30.
The findings from the original study were reported in the Lancet in 2011. The first patient to receive the systemic injection of this novel compound was performed in the BRC-supported Somers Clinical Research Facility at GOSH.
Engineered tissue offers hope for children born with ‘missing’ food pipe
Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown oesophagus - the food pipe - shown to safely replace a full section of the organ and restore normal function, including swallowing, in
GOSH celebrates Rare Disease Day 2026 with local community
GOSH specialises in rare disease research and to celebrate, we recently invited two local North London Year 4 classes to join us for the day to learn about how we care for patients with rare diseases.
Professor Francesco Muntoni wins prestigious research prize
Professor Francesco Muntoni, GOSH Paediatric Neurology Consultant, has been awarded the 2026 Novo Nordisk Prize in recognition of his pioneering work transforming the outlook for children with Duchenne muscular dystrophy (DMD).
GOSH secures £1.4m in NIHR capital equipment funding to boost research capability
This investment will significantly strengthen our research infrastructure and enhance our ability to deliver world‑leading paediatric research across the whole hospital.